Becton, Dickinson and Company (NYSE:BDX) Holdings Raised by Bank of Nova Scotia

Bank of Nova Scotia lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 22.1% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 163,650 shares of the medical instruments supplier’s stock after buying an additional 29,576 shares during the quarter. Bank of Nova Scotia owned about 0.07% of Becton, Dickinson and worth $31,930,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. State Street Corp increased its stake in Becton, Dickinson and by 3.5% in the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after acquiring an additional 342,873 shares during the last quarter. Peapack Gladstone Financial Corp increased its stake in Becton, Dickinson and by 1.3% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock worth $7,116,000 after acquiring an additional 453 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in Becton, Dickinson and by 35.3% in the 2nd quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock worth $8,447,000 after acquiring an additional 11,300 shares during the last quarter. Bessemer Group Inc. increased its stake in Becton, Dickinson and by 1.4% in the 2nd quarter. Bessemer Group Inc. now owns 978,050 shares of the medical instruments supplier’s stock worth $190,827,000 after acquiring an additional 13,263 shares during the last quarter. Finally, Fundsmith LLP increased its stake in Becton, Dickinson and by 0.3% in the 2nd quarter. Fundsmith LLP now owns 2,302,590 shares of the medical instruments supplier’s stock worth $449,258,000 after acquiring an additional 5,977 shares during the last quarter. 86.71% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Becton, Dickinson and Company (NYSE:BDX) Holdings Raised by Bank of Nova Scotia” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/11/bank-of-nova-scotia-has-31-93-million-position-in-becton-dickinson-and-company-bdx.html.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded down $5.25 during trading hours on Friday, reaching $219.23. The company had a trading volume of 1,773,100 shares, compared to its average volume of 1,336,567. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $225.23. The firm has a market cap of $51,083.79, a price-to-earnings ratio of 23.65, a P/E/G ratio of 1.76 and a beta of 1.04. The company has a quick ratio of 5.01, a current ratio of 5.56 and a debt-to-equity ratio of 1.48.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. During the same period in the prior year, the company posted $2.12 EPS. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. equities analysts predict that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

In other news, insider Stephen Sichak sold 11,787 shares of the company’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the sale, the insider now owns 14,038 shares in the company, valued at $2,814,057.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Ribo Alberto Mas sold 7,463 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $201.41, for a total value of $1,503,122.83. Following the completion of the sale, the executive vice president now owns 29,323 shares in the company, valued at approximately $5,905,945.43. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,650 shares of company stock worth $12,223,970. Company insiders own 1.40% of the company’s stock.

A number of equities analysts have recently commented on BDX shares. Wells Fargo & Company reiterated a “positive” rating and issued a $235.00 target price (up previously from $225.00) on shares of Becton, Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. BidaskClub cut Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reiterated a “buy” rating and issued a $213.00 target price on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Morgan Stanley boosted their price objective on Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Bank of America Corporation restated a “buy” rating and set a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Becton, Dickinson and currently has an average rating of “Buy” and an average target price of $213.47.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply